Skip to main content
NewslettersWatchlist

Teva Pharmaceutical Industries ADR(TEVA-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low13.83
Day High14.33
Open:13.83
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Forget Nvidia: 3 Prominent Billionaire Investors Are Selling It and Buying These 6 Value Stocks Instead
Motley Fool
3 No-Brainer Stocks to Buy With $600 Right Now
Motley Fool
Teva Pharmaceutical Industries (TEVA) Q4 2023 Earnings Call Transcript
Motley Fool
My 5 Largest Portfolio Holdings for 2024
MarketBeat
2 overlooked stocks that crushed earnings but traded lower
Motley Fool
Teva Pharmaceutical Industries (TEVA) Q3 2023 Earnings Call Transcript
Motley Fool
3 No-Brainer Stocks to Buy With $20 Right Now
Motley Fool
Teva Pharmaceutical Industries (TEVA) Q2 2023 Earnings Call Transcript
Motley Fool
3 Bargain Stocks to Buy on the Dip
Motley Fool
Is AbbVie or Amgen the Better Bargain Buy Right Now?
Motley Fool
Teva Pharmaceuticals Just Made a Big Announcement, but Is It a Buy?
Motley Fool
Why Teva Pharmaceutical Stock Is Jumping Today
Motley Fool
Teva Pharmaceutical Industries (TEVA) Q1 2023 Earnings Call Transcript
Business Wire
U.S. Mental Health Access Program Expands Medicine Donation to Seven New States
Business Wire
Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults
Business Wire
Teva to Launch New Growth Strategy at Investor Day
Motley Fool
1 "Safe" Stock to Avoid and 1 to Consider Buying in April
Business Wire
Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023
Business Wire
Complete Response Letter Received for AVT02 Biologics License Application
Business Wire
Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual Meeting
Business Wire
Teva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health System
Motley Fool
3 No-Brainer Stocks to Buy With $10 Right Now
Business Wire
Teva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Early Settlement
Business Wire
Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
TheNewswire.com
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
Business Wire
Teva to Present at the Barclays Global Healthcare Conference
Motley Fool
Better Generics Pharmaceutical Stock: Teva or Viatris?
Business Wire
Teva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Senior Notes and the Increase of the Maximum Tender Amount of its Debt Tender Offer
Business Wire
Teva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior Notes
Business Wire
Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026
Business Wire
Teva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting
Business Wire
Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact of Tardive Dyskinesia on Patients’ Lives

Profile

Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.